Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRas^G12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.

中文翻译：

---

c-Raf在KRas突变癌中：一个移动的目标。

用于KRas癌症的疗法仍然是主要的临床需求。在本期《癌细胞》中，Mariano Barbacid小组的Sanclemente及其同事证实c-Raf是这些癌症的主要靶标。c-Raf消融可导致晚期KRas ^G12V / Trp53肿瘤消退，而没有明显的全身毒性并且不影响MAPK信号传导。